drugset / Trial / NCT00019097

Vaccine Therapy in Treating Patients With Multiple Myeloma

NCT00019097

Treatment

Summary

RATIONALE: Vaccines made from a person's tumor cells may make the body build an immune response and kill their tumor cells. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy used to kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of peripheral stem cell transplantation plus vaccine therapy and chemotherapy in treating patients who have multiple myeloma.

Timeline

Start
1995-07
Primary completion
Completion
2007-03

Drugs

EvaluationDrugModalityDoseRoute
Subject autologous tumor cell vaccine Vaccine Subcutaneous
Subject keyhole limpet hemocyanin Vaccine Subcutaneous
Subject sargramostim Protein / enzyme biologic Subcutaneous
Background Melphalan Small molecule Intravenous

Indications